Mantle cell lymphoma

This study tests a new combination of three drugs—ALX148, lenalidomide, and rituximab—in people with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to find the best dose and see how well the combo works at shrinking or eliminating tumors…

This early-phase study tests a combination of three drugs (ibrutinib, lenalidomide, and rituximab) in people with mantle cell lymphoma that has returned or not responded to prior treatment. The main goal is to find the safest dose of this combination by monitoring side effects. U…

This early-phase trial is testing a new type of immunotherapy called tri-specific CAR T-cells that target three proteins (CD19, CD20, CD22) on cancer cells. It is for adults with B-cell lymphomas that have come back or not responded to standard treatments. The study will enroll 1…

This study tests whether a stem cell transplant followed by the drug rituximab works better than rituximab alone for people with mantle cell lymphoma whose cancer is in first complete remission. About 689 adults aged 18 to 70 are taking part. The goal is to see which approach hel…

This study tests three different chemotherapy combinations in people aged 70 or younger with newly diagnosed mantle cell lymphoma, a type of blood cancer. The goal is to see if adding a targeted drug called acalabrutinib to standard chemo improves how well the cancer responds. Ar…

This study tests a new treatment for people with high-risk B-cell non-Hodgkin lymphoma that has come back. After a stem cell transplant, patients receive genetically modified immune cells designed to recognize and attack cancer cells. The goal is to see if this approach is safe a…

Researchers are testing whether adding an experimental drug called rocbrutinib to standard R-CHOP chemotherapy is safe and shows early signs of helping adults newly diagnosed with certain B-cell non-Hodgkin lymphomas. The trial enrolls about 112 participants who have not yet rece…

This trial tests an antibody called epcoritamab in 666 people with B-cell lymphoma that has come back or not responded to treatment. The drug is designed to help the immune system attack cancer cells. The study looks at safety, the right dose, and how well the drug works.

This early-stage study is testing a combination of three drugs (alisertib, bortezomib, and rituximab) in about 24 people with mantle cell or low-grade non-Hodgkin lymphoma that has returned or stopped responding to prior treatments. The main goal is to find the safest dose of the…

This Phase 2 trial is testing a combination of three drugs—zanubrutinib, obinutuzumab, and venetoclax—in people with previously untreated chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or mantle cell lymphoma (MCL). The goal is to see if the combo can make …

This phase 2 trial tests a combination of three drugs—acalabrutinib, venetoclax, and rituximab—in 108 people with untreated mantle cell lymphoma. The goal is to see if the treatment can make the cancer undetectable in the blood (MRD-negative) after about a year. Those who achieve…

This phase 2 trial tests a drug called mosunetuzumab, given as a shot under the skin, for people with certain types of non-Hodgkin lymphoma. The study includes 320 participants and aims to see if the drug can shrink tumors or delay cancer growth. Researchers are also checking for…

This phase 2 trial tests whether adding venetoclax to ibrutinib and an anti-CD20 antibody can better clear minimal residual disease in people with newly diagnosed mantle cell lymphoma. About 210 patients will receive either the two-drug or three-drug combo for up to two years, pl…

This trial tests whether adding acalabrutinib—a targeted drug that blocks a key enzyme in cancer cells—to a standard chemotherapy cocktail (modified VR-CAP) can improve outcomes for people with mantle cell lymphoma who are eligible for a stem cell transplant. The study enrolls ad…

This phase 2 trial is testing whether the drug loncastuximab tesirine, given after a short course of chemotherapy, can help people with mantle cell lymphoma whose cancer has returned or not responded to previous treatments, including BTK inhibitors. About 49 participants will rec…

This phase 2 trial is testing a new drug called zilovertamab vedotin (MK-2140), alone or with another drug nemtabrutinib, in about 189 people with several types of B-cell blood cancers that have come back or not responded to prior treatments. The main goals are to see if the trea…

This early-phase trial is testing a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells. It is for people with certain B-cell lymphomas or chronic lymphocytic leukemia that have come back or not responded to standard treatments. The therapy in…

This study tests an experimental drug called CHO-H01, alone or with lenalidomide, in people with non-Hodgkin lymphoma that has returned or not responded to prior treatments. The trial has two parts: first, finding a safe dose of CHO-H01 alone; second, testing the combination in l…

This early-stage trial is testing a new drug called ABBV-291 in adults with Non-Hodgkin's lymphoma that has come back or stopped responding to treatment. The study will first find the safest dose, then check if the drug can shrink tumors. About 165 participants will take part wor…

This early-phase trial is testing a two-step approach for people with newly diagnosed, high-risk mantle cell lymphoma. First, patients receive a combination of acalabrutinib (a targeted drug) and rituximab (an antibody). Then, they get a one-time infusion of their own genetically…

This phase II trial is testing two oral drugs, venetoclax and acalabrutinib, in 32 people with mantle cell lymphoma that has returned or not responded to prior treatment. The goal is to see if the combination can shrink tumors and control the disease. Both drugs work by blocking …

This study tests a combination of two drugs, acalabrutinib and rituximab, in people aged 65 and older with newly diagnosed mantle cell lymphoma who haven't had treatment yet. Acalabrutinib blocks enzymes that help cancer grow, while rituximab targets and kills cancer cells. The g…

This early study tests a new drug called ABBV-101 in people with several types of non-Hodgkin lymphoma that have come back or not responded to other treatments. The drug is a pill that targets a protein (BTK) involved in cancer growth. The main goals are to find a safe dose and s…

This study tests a drug called ACP-196 (acalabrutinib) in 124 adults with mantle cell lymphoma that has returned or not responded to prior therapy. The main goal is to see how many patients have their tumors shrink or disappear. This is an open-label, phase 2 trial, meaning every…

This Phase 2 trial tests an investigational drug called odronextamab in 515 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The drug is designed to help the immune system attack cancer cells. The main goal is to see if it shrinks tumors a…

This phase II study tests a combination of two drugs, palbociclib and ibrutinib, in 39 patients with mantle cell lymphoma that has been treated before. The goal is to see if the combo can delay cancer progression. Patients take both pills daily in 28-day cycles.

This phase 2 trial tests whether adding isatuximab to standard stem cell transplant procedures can help the immune system better fight multiple myeloma and certain lymphomas. Participants are randomly assigned to receive either standard transplant care alone or isatuximab plus st…

This early-stage trial tests a new three-drug combination (ibrutinib, rituximab, and bendamustine) in adults with certain types of non-Hodgkin lymphoma that have come back after prior treatment. The main goal is to find the safest dose of ibrutinib when given with the other two d…

This phase II trial tests a combination of three targeted drugs—acalabrutinib, umbralisib, and ublituximab—in people with previously untreated mantle cell lymphoma. The drugs work by blocking signals that help cancer cells grow and by helping the immune system attack them. The st…

This phase II trial tests the drug ibrutinib in 20 people with untreated, high-risk smoldering mantle cell lymphoma (MCL), a slow-growing blood cancer. The goal is to see if ibrutinib can stop the cancer from progressing by blocking enzymes that help cancer cells grow. Participan…

This study tests whether a very low dose of radiation (4 Gy) can control slow-growing B-cell lymphoma in the eye socket. About 50 adults with stage I-IV indolent lymphoma or mantle cell lymphoma will receive this targeted treatment. The goal is to shrink or stop the cancer while …

This early-stage trial tests two new drug combinations for people with untreated mantle cell lymphoma, a rare blood cancer. One group gets acalabrutinib plus standard chemo and an antibody; the other gets acalabrutinib plus a targeted pill and the same antibody. The main goal is …

This early-phase trial tests a new approach to treating certain blood cancers (like lymphoma and leukemia) that have come back or not responded to standard treatment. The therapy uses a patient's own immune cells, engineered to recognize and attack cancer cells (SYNCAR-001), alon…

This phase II trial tests the drug pemigatinib (Pemazyre) in 27 adults with relapsed or refractory B-cell non-Hodgkin lymphomas, including mantle cell and marginal zone lymphoma. Participants take one pill daily in 28-day cycles. The main goal is to see if the drug can shrink tum…

This study tests a two-drug combination (ibrutinib and rituximab) in people with mantle cell lymphoma that has returned or not responded to treatment, or in older adults newly diagnosed. The goal is to shrink or control the cancer. About 113 participants will receive the drugs to…

This study tests an experimental drug called epcoritamab given together with other anti-cancer medicines in adults with Non-Hodgkin lymphoma (NHL), a type of blood cancer. About 496 participants will receive different combinations depending on their lymphoma subtype and treatment…

This study tests a two-step treatment for people with relapsed or refractory B-cell Non-Hodgkin lymphoma. First, patients receive a bispecific antibody therapy (Obinutuzumab and Glofitamab) to help the immune system attack cancer cells. Then, they get an infusion of CD19-CAR T ce…

This study tests a combination of two drugs, ixazomib and rituximab, in people with slow-growing B-cell non-Hodgkin lymphoma. The goal is to see how well the drugs shrink or control the cancer. About 33 adults with different types of this lymphoma are taking part.

This early-phase trial is testing whether combining three drugs—tazemetostat, zanubrutinib, and an anti-CD20 antibody (rituximab or obinutuzumab)—is safe and effective for people with certain types of lymphoma that have come back or not responded to treatment. The study involves …

This phase 2 study tests a single infusion of KTE-X19, a CAR T-cell therapy, in 25 Japanese adults whose mantle cell lymphoma or B-cell acute lymphoblastic leukemia has returned or not responded to prior treatments. The goal is to see how well it shrinks tumors and how safe it is…

This Phase 2 trial is testing a combination of three drugs—pirtobrutinib, rituximab, and venetoclax—as a first treatment for people with mantle cell lymphoma who have not had any prior therapy. The goal is to see how many patients achieve a complete response (no cancer detected) …

This phase II trial tests whether combining three drugs—bendamustine, obinutuzumab, and venetoclax—can improve outcomes for people with untreated mantle cell lymphoma. Bendamustine and venetoclax are chemotherapy drugs that kill or stop cancer cells from growing, while obinutuzum…

This phase I trial tests a new approach for patients with high-risk or recurrent non-Hodgkin lymphoma. After a stem cell transplant, participants receive a single infusion of their own genetically modified T-cells designed to recognize and attack cancer cells. The study aims to f…

This early-phase study tests a new drug called BGB-11417 (sonrotoclax) in people with B-cell blood cancers that have come back or not responded to treatment. The goal is to find the safest dose and see how well it works alone or combined with other drugs. About 437 adults will ta…

This phase 2 trial is testing a combination of two drugs, acalabrutinib and rituximab, in elderly or frail patients who have not yet been treated for mantle cell lymphoma. The goal is to see how well the drugs shrink or control the cancer. The study involves 48 participants aged …

This study tests a treatment made from a patient's own immune cells, which are genetically modified to recognize and attack a protein called CD20 on cancer cells. It is for people with B-cell non-Hodgkin lymphoma that has returned or not responded to prior therapy. The main goals…

This trial explores whether adding the drug tazemetostat (Tazverik) to standard CAR T cell therapy can help the immune cells better recognize and destroy lymphoma cells. It enrolls people with diffuse large B-cell lymphoma, follicular lymphoma, or mantle cell lymphoma who have al…

This early-phase trial tests whether adding special immune cells called veto cells to a stem cell transplant can help donor cells grow in the patient without causing severe graft-versus-host disease (GVHD). The study includes 16 people with various blood cancers or bone marrow fa…

This phase II trial tests whether adding the targeted drug acalabrutinib to standard R-CHOP chemotherapy improves outcomes for people with untreated mantle cell lymphoma. About 105 participants will receive the combination, then some will proceed to stem cell transplant. The stud…

This study tests a daily oral drug called nemtabrutinib (ARQ 531) in 190 people with blood cancers like lymphoma or leukemia that have come back or not responded to prior treatment. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-phase trial,…

This study tested a two-step drug combination for people newly diagnosed with mantle cell lymphoma, a type of blood cancer that is not curable with standard treatments. Twenty-three patients who were eligible for a stem cell transplant received rituximab and bendamustine followed…

This study tests a new drug called orelabrutinib in people with B-cell malignancies, such as certain lymphomas and leukemias. The drug works by blocking a protein that helps cancer cells grow. The trial has two parts: first finding the safest dose, then seeing how well it shrinks…

This phase II trial tests whether ultra low dose radiation, given before or after chemotherapy-free targeted therapy, can help control mantle cell lymphoma that has returned or stopped responding to treatment. About 51 adults with measurable disease will receive the radiation, an…

This phase 2 trial tests four different drug combinations in 373 patients aged 60 and older with untreated mantle cell lymphoma. The goal is to see which combination best delays cancer progression. Patients receive rituximab plus bendamustine, with or without bortezomib, followed…

This phase 3 trial tests whether adding the targeted drug acalabrutinib to standard chemotherapy (bendamustine and rituximab) helps people with untreated mantle cell lymphoma live longer without their cancer getting worse. About 635 patients aged 65 and older are taking part. The…

This study tests a stem cell transplant from a matched unrelated donor for people with advanced blood cancers or blood disorders. Patients get chemotherapy and radiation before the transplant to prepare their body, then take drugs to prevent the donor cells from attacking their o…

This early-phase trial tests the safety and best dose of combining ibrutinib and palbociclib in 28 patients with mantle cell lymphoma that has come back after treatment. Both drugs block enzymes that help cancer cells grow. The study aims to find a dose that is safe enough to tes…

This study tests a combination of targeted therapy (ibrutinib) and immunotherapy (rituximab) followed by strong chemotherapy in young patients with newly diagnosed mantle cell lymphoma, an aggressive blood cancer. The goal is to see if this approach improves response rates while …

This phase II trial is testing a combination of targeted drugs (ibrutinib, rituximab, venetoclax) plus chemotherapy in 51 newly diagnosed young adults with mantle cell lymphoma. The goal is to see if this approach can achieve a complete response—meaning no signs of cancer—after t…

This early-phase trial tests a gene therapy approach for people with HIV who also have lymphoma that has returned or not responded to treatment. Researchers take the patient's own stem cells, add anti-HIV genes in the lab, and return them after a stem cell transplant. The goal is…

This study tests whether a new drug combination (zanubrutinib plus rituximab) works better than standard chemotherapy (bendamustine plus rituximab) for people with untreated mantle cell lymphoma who cannot have a stem cell transplant. About 510 participants will be randomly assig…

This study tests a new drug called pirtobrutinib against other approved drugs for mantle cell lymphoma, a type of blood cancer. About 500 people who have already had at least one prior treatment will take part. The goal is to see if the new drug works better at controlling the di…

This study tests a combination of three drugs (obinutuzumab, zanubrutinib, and lenalidomide) followed by a short course of chemotherapy (cytarabine) in 39 adults newly diagnosed with mantle cell lymphoma, a rare blood cancer. The goal is to see if this approach can shrink or elim…

This early-phase trial is testing a combination of two drugs, ibrutinib and lenalidomide, in people with B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The main goal is to find the safest dose and understand side effects. About 39 participants with d…

This early-stage trial is testing an experimental oral drug called APG-2575 in people with relapsed or refractory chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). The main goal is to check the drug's safety and find the best dose. About 74 participants will take…

This early-phase study tests a new two-drug combination (pevonedistat and ibrutinib) in adults with chronic lymphocytic leukemia or non-Hodgkin lymphoma that has returned or no longer responds to standard therapy. The main goal is to find the safest dose and understand side effec…

This phase 2 trial tests a combination of three drugs—acalabrutinib, lenalidomide, and either rituximab or obinutuzumab—in people with untreated mantle cell lymphoma. The goal is to see how well the combo clears cancer cells from the blood and shrinks tumors. Participants receive…

This study tests a combination of two drugs, copanlisib and venetoclax, in adults with mantle cell lymphoma that has returned or stopped responding to treatment. The goal is to find the safest dose and see how well the drugs shrink tumors. Eight participants are enrolled in this …

This study tests a drug called acalabrutinib in Chinese adults with certain blood cancers (mantle cell lymphoma, chronic lymphocytic leukemia, or other B-cell cancers) that have come back or not responded to treatment. The trial has two parts: the first checks safety and how the …

This early-stage trial is testing an experimental therapy called NKX019 for people with certain blood cancers (like lymphoma and leukemia) that have come back or not responded to standard treatments. NKX019 uses donor immune cells (natural killer cells) that are engineered to fin…

This study tests a drug called acalabrutinib in people with mantle cell lymphoma who had to stop taking ibrutinib because of bad side effects. The goal is to see if acalabrutinib can shrink or control the cancer without causing the same problems. About 9 participants will receive…

This early-phase trial tests a two-part treatment for people with relapsed or chemotherapy-resistant B-cell leukemia or lymphoma. First, patients receive a chemotherapy drug (cyclophosphamide) to help prepare the body. Then, they get an infusion of their own T cells that have bee…

This early-phase trial tests a new approach for patients with aggressive B-cell lymphoma that has come back after treatment. Researchers take a patient's own immune cells (T cells), modify them in the lab to better recognize and kill lymphoma cells, and give them back after a sta…

This pilot study tests whether combining glofitamab (an IV drug) with lenalidomide (an oral drug) is a feasible treatment for people with mantle cell lymphoma that has returned or not responded to prior therapy, including a BTK inhibitor. The study enrolls 39 adults and focuses o…

This phase 2 trial is testing a combination of two drugs—ibrutinib and rituximab—in 50 people with untreated, slow-growing mantle cell lymphoma. The goal is to see if this drug pair can shrink or eliminate the cancer and keep it from progressing. Researchers will also study the t…

This study tests an experimental drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphomas) that have come back or not responded to standard treatments. The drug delivers radiation directly to cancer cel…

This study tests an experimental drug called valemetostat tosylate in people with B-cell lymphoma whose cancer has returned or not responded to prior treatments. About 141 participants will receive the drug to see if it can shrink tumors. The goal is to find a new option for hard…

This study tests a modified plan to prevent and treat cytomegalovirus (CMV) infection in people with blood cancers who have had a donor stem cell transplant. CMV is a common virus that can cause serious problems after transplant. The study involves 153 participants and looks at w…

This study tests whether adding the drug vorinostat to standard care can prevent graft-versus-host disease (GVHD) in children, adolescents, and young adults receiving a bone marrow or blood stem cell transplant for blood cancers. Researchers are first finding the best dose of vor…

This phase 2 trial tests an oral drug called rocbrutinib in 62 people with mantle cell lymphoma that has come back or not responded to other treatments. Participants take the drug once daily until their disease worsens or side effects become too severe. The main goal is to see ho…

This early-stage trial tests a new lab-made antibody called BYON4228, alone or with the cancer drug rituximab, in 17 people with relapsed or refractory B-cell non-Hodgkin lymphoma. The goal is to check safety and find the right dose. It's the first time this drug is being tested …

This study tests a new stem cell treatment (MGTA-456) made from umbilical cord blood for people with high-risk blood cancers like leukemia and lymphoma. About 22 patients will receive high-dose chemotherapy followed by the stem cell infusion. The goal is to see if this treatment …

This early-phase trial tests SC262, a therapy made from donor immune cells (CAR T cells) designed to attack a protein called CD22 on lymphoma cells. It is for people with non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The main goal is to check …

This study tests whether the drug anakinra can prevent or reduce severe side effects like brain problems and cytokine release syndrome caused by CAR-T cell therapy. About 62 adults with certain B-cell blood cancers who are getting CAR-T treatment will receive anakinra. The goal i…

This early-stage trial tests a new cellular immunotherapy for adults with certain B-cell cancers (like lymphomas and leukemias) that have come back. Researchers take a patient's own white blood cells, modify them in the lab to better recognize and attack cancer cells, and infuse …

This early-phase study tests SC291, a CAR T-cell therapy made from donor cells, in 16 adults with relapsed or refractory B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia. The goal is to check safety and see if the treatment can shrink tumors. Because it uses donor cell…

This early-phase trial is testing whether combining two drugs—nivolumab (a monoclonal antibody) and lenalidomide (a chemotherapy-like drug)—can safely and effectively treat people with non-Hodgkin or Hodgkin lymphoma that has returned or is not responding to treatment. The study …

This study tests adding a drug called selinexor to the standard chemotherapy RCHOP for people with B-cell non-Hodgkin lymphoma. The goal is to find the safest dose and see if the combination works better than standard treatment alone. About 43 adults with advanced or returning ly…

This early-stage trial tests a personalized therapy where a patient's own immune cells are genetically modified to recognize and attack cancer cells that carry a protein called CD19. It includes adults with certain types of leukemia, lymphoma, or chronic lymphocytic leukemia that…

This early-phase trial is testing a new type of immunotherapy for people with B-cell Non-Hodgkin's lymphoma that has returned or not responded to treatment. The therapy uses a patient's own immune cells, which are modified in the lab to target two proteins (CD19 and CD20) on canc…

This study tests a drug called sonrotoclax (BGB-11417) in 125 people with mantle cell lymphoma that has relapsed or not responded to prior treatments. The trial has two parts: first to find the safest dose, then to see how well it shrinks tumors. Participants take the drug by mou…

This trial is testing a new imaging tracer called FLT, which is used with a PET scan to measure how fast tumors are growing. The study includes people with various cancers or those awaiting a biopsy for a suspicious mass. The goal is to see if FLT PET imaging can help find and di…

This study looks at whether a liquid biopsy (a simple test that checks for cancer DNA in spinal fluid) can better detect and monitor brain involvement in people with high-risk B-cell non-Hodgkin lymphoma. Researchers will compare this new method to standard tests in 64 newly diag…

This observational study tracks about 160 Chinese adults with mantle cell lymphoma (MCL) or chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who take acalabrutinib as part of their normal care. Researchers will record how the drug is used, including doses and com…

This study tests whether a wearable patch called TempTraq can detect fevers earlier than standard temperature checks in cancer patients receiving immunotherapy. The goal is to see if continuous monitoring reduces the risk of severe cytokine release syndrome (CRS), a serious side …

This study follows 50 people who have already received an experimental CAR T cell therapy for certain blood cancers like lymphoma. No new treatment is given; instead, researchers will check for long-term side effects and how well the therapy works over 15 years. The goal is to be…

This study examines stored tissue samples from 160 adults with mantle cell lymphoma whose cancer returned or didn't respond after initial chemotherapy and rituximab. Researchers will analyze the samples to identify genetic and cellular features linked to treatment resistance. The…

This study is testing whether a blood test that looks for tumor DNA (called ctDNA) can predict if lymphoma will come back after first treatment. Researchers will compare this 'liquid biopsy' to standard PET scans in 108 adults with B-cell or Hodgkin lymphoma. The goal is to see i…